Tag Archives: post-bariatric hypoglycemia

Amylyx’s GLP-1 Antagonist Wins in Ph3 Post-Bariatric Surgery Hypoglycemia Study

Amylyx Pharmaceuticals announced positive topline results from the Ph3 LUCIDITY trial (view CT.gov record) evaluating the efficacy and safety of 90mg avexitide (QD SC GLP-1R antagonist) in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery (a common type of bariatric surgery). Below, FENIX provides highlights and insights from the results.

This content is for Read Less members only.
Already a member? Log in here

Altimmune Initiates PERFORMA; Amylyx Launches PBH Awareness Campaign; Vertex Q2 ’26 Earnings

Three cardiometabolic-related news items have been observed: Altimmune initiated the pivotal Ph3 PERFORMA trial in F2-F3 MASH (view press release); Amylyx Pharmaceuticals launched a post-bariatric hypoglycemia education website (view article); and Vertex Pharmaceuticals hosted its Q2 ’26 earnings call, disclosing a new T1DM cell therapy program (view press release; slides).

This content is for Read Less members only.
Already a member? Log in here